Current Challenges in Designing GBM Trials for Immunotherapy

Overview

Journal J Neurooncol

Publisher Springer

Date 2015 Jan 12

PMID 25577401

Citations 21

Authors

Shiao-Pei Weathers

Mark R Gilbert

Affiliations

Soon will be listed here.

Abstract

Immune system modulation is evolving into a promising treatment modality in glioblastoma. Our growing understanding of glioma immunobiology has fueled efforts to develop immunotherapeutic strategies to combat this lethal primary brain tumor. Autologous stimulated lymphocytes, immunotherapy with cytokines and dendritic cells, immune checkpoint inhibitors, virotherapy, and tumor or peptide based vaccines are immunotherapy approaches under active investigation. A number of challenges are evident in the design of immunotherapy clinical trials in glioblastoma including patient selection, immune and imaging response monitoring, and evaluation of clinical outcome.

Citing Articles

An enzyme-responsive double-locked amonafide prodrug for the treatment of glioblastoma with minimal side effects.

Cheng W, Yang Y, Zhang B, Shao C, Chen W, Xia R Chem Sci. 2024; .

PMID: 39494374 PMC: 11528907. DOI: 10.1039/d4sc04555f.

Isotoxic dose escalated radiotherapy for glioblastoma based on diffusion-weighted MRI and tumor control probability-an in-silico study.

Pang Y, Kosmin M, Li Z, Deng X, Li Z, Li X Br J Radiol. 2023; 96(1146):20220384.

PMID: 37102792 PMC: 10230387. DOI: 10.1259/bjr.20220384.

Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial.

Lepski G, Bergami-Santos P, Pinho M, Chauca-Torres N, Evangelista G, Teixeira S Cancers (Basel). 2023; 15(4).

PMID: 36831580 PMC: 9953909. DOI: 10.3390/cancers15041239.

An Unusual Case of Glioblastoma Multiforme, Presenting as Skeletal Superscan.

Bishnoi K, Parida G, Thavnani R, Patro P, Agrawal K Indian J Nucl Med. 2023; 37(3):268-270.

PMID: 36686309 PMC: 9855241. DOI: 10.4103/ijnm.ijnm_209_21.

Prediction of radiosensitivity and radiocurability using a novel supervised artificial neural network.

Zeng Z, Luo M, Li Y, Li J, Huang Z, Zeng Y BMC Cancer. 2022; 22(1):1243.

PMID: 36451111 PMC: 9713966. DOI: 10.1186/s12885-022-10339-3.

References

Tada M, Suzuki K, Yamakawa Y, Sawamura Y, Sakuma S, Abe H . Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)). J Neurooncol. 1993; 16(1):25-34. DOI: 10.1007/BF01324831. View

Liau L, Black K, Martin N, Sykes S, Bronstein J, Jouben-Steele L . Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2006; 9(6):e8. DOI: 10.3171/foc.2000.9.6.9. View

Li Y, Wang L, Yang G, Hao F, Urba W, Hu H . Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008; 68(17):6889-95. PMC: 2905686. DOI: 10.1158/0008-5472.CAN-08-0161. View

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

Dunn G, Dunn I, Curry W . Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007; 7:12. PMC: 2935751. View

Jiang H, White E, Rios-Vicil C, Xu J, Gomez-Manzano C, Fueyo J . Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol. 2011; 85(10):4720-9. PMC: 3126198. DOI: 10.1128/JVI.02032-10. View

Orgogozo J, Gilman S, Dartigues J, Laurent B, Puel M, Kirby L . Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003; 61(1):46-54. DOI: 10.1212/01.wnl.0000073623.84147.a8. View

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

Weber J, Kahler K, Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21):2691-7. DOI: 10.1200/JCO.2012.41.6750. View

10.

Zitvogel L, Galluzzi L, Smyth M, Kroemer G . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013; 39(1):74-88. DOI: 10.1016/j.immuni.2013.06.014. View

11.

Murat A, Migliavacca E, Gorlia T, Lambiv W, Shay T, Hamou M . Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008; 26(18):3015-24. DOI: 10.1200/JCO.2007.15.7164. View

12.

Schartz N, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A . Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 2010; 20(3):247-50. DOI: 10.1097/CMR.0b013e3283364a37. View

13.

Drake C . Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010; 10(8):580-93. PMC: 3082366. DOI: 10.1038/nri2817. View

14.

Heimberger A, Sampson J . Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol. 2010; 13(1):3-13. PMC: 3018912. DOI: 10.1093/neuonc/noq169. View

15.

Bullard D, Gillespie G, MAHALEY M, Bigner D . Immunobiology of human gliomas. Semin Oncol. 1986; 13(1):94-109. View

16.

Brooks W, NETSKY M, Normansell D, Horwitz D . Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med. 1972; 136(6):1631-47. PMC: 2139329. DOI: 10.1084/jem.136.6.1631. View

17.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

18.

Jiang H, Gomez-Manzano C, Aoki H, Alonso M, Kondo S, McCormick F . Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007; 99(18):1410-4. DOI: 10.1093/jnci/djm102. View

19.

Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle K . Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013; 31(32):4085-91. PMC: 3816958. DOI: 10.1200/JCO.2013.49.6968. View

20.

Galea I, Bechmann I, Perry V . What is immune privilege (not)?. Trends Immunol. 2006; 28(1):12-8. DOI: 10.1016/j.it.2006.11.004. View